ZCZC
BFF-39
INDIA-HEALTH-TUBERCULOSIS-MEDICINE
TB drug price slashed in global push to thwart killer disease
HYDERABAD, India, Oct 31, 2019 (BSS/AFP) – A pharmaceutical multinational
on Thursday slashed the price of a key anti-tuberculosis drug boosting the
battle against the world’s deadliest infectious disease, as a new treatment
was also set to begin extensive testing.
The initiatives came as the United Nations seeks to galvanise the campaign
against TB, which killed 1.5 million people worldwide last year and saw 10
million more infected.
“This lifesaving drug has, until now, been completely unaffordable in
developing countries,” said Lelio Marmora, head of Unitaid, a global health
initiative that helped broker the landmark deal, which will see the Sanofi
company cut the price of its rifapentine drug by two thirds.
The cheaper price will apply in 100 of the world’s poorest nations. South
Africa, where TB is a big killer, will roll out the drug from next year,
Unitaid’s programme director Robert Matiru told AFP.
Other major markets that could take up the treatments include India, which
has a quarter of the world’s TB cases, Indonesia, Philippines and Kenya,
Sanofi’s global health business chief Thibaud Lefort told AFP.
“We are looking realistically next year at adding at least five major
countries and a dozen other smaller countries accelerating their efforts,” he
said.
– TB resistance –
Lefort said his firm welcomed generic versions of the drug being produced.
Aid agencies have become increasingly frustrated at the slow pace of
fighting the disease, which the UN hopes to eradicate by 2030.
The existing TB vaccine is almost a century old and only good for limited
numbers of patients and forms of the illness.
The battle has been held up by some TB strains becoming resistant to drugs.
“The reason drug-resistant TB is such a problem is because it is so much
more difficult to treat, it costs so much more to treat and also… the
morbidity and mortality is much higher,” NIH’s Peter Kim told AFP.
Rifapentine, combined with the drug isoniazid, not only treats patients
with TB, but also shields a person who is infected but not yet sick from
developing the disease.
With one quarter of the world’s population carrying the TB infection, and
up to 10 percent of them going on to develop the chronic lung disease,
experts say preventive drugs such as rifapentine are central to eradicating
the illness.
Only 1.8 million people are on preventive TB therapies, but a UN health
summit last year set a target of 30 million people to be on such drugs by
2022, Matiru said.
Activists at a global lung health conference in Hyderabad, also called for
the price of tests used for TB diagnosis to be halved to $5 to make it more
affordable for poorer nations.
The price cut follows an announcement earlier this week by Britain’s
GlaxoSmithKline that a new vaccine tested in adults in three African nations
had shown particular promise.
The treatment had 50 percent effectiveness three years after it was given
to participants in Kenya, South Africa and Zambia who already have TB
bacteria but have not fallen ill.
And the US National Institutes of Health (NIH) said Thursday it was
launching a huge trial across more than 12 countries for people exposed to
drug-resistant strains of TB.
The study will test a new drug on vulnerable populations such as children
and those with weakened immune systems, including HIV-positive people.
BSS/AFP/SSS/1711 hrs